CTL was founded in 2009 by Nobel Laureate Professor Sir Martin Evans and former global head of emerging technologies at Swiss pharma giant Roche, Ajan Reginald.

The Wales-based company's disruptive technology platform drives in-house discovery and manufacture of a pipeline of novel tissue-specific regenerative medicines. CTL is currently in the process of re-branding under the name Celixir.